Physician profile
Dakin White
NPI 1578150363
$4,873.89
in general payments reported to CMS, 2019-2025
18 companies · $3,632 in 2025
The $3,632 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,242 · 2025: $3,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,852 · Education: $22.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,851.62 |
| Education | $22.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,488.25 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $585.64 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $450.14 | 2024-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $377.48 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $354.23 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $347.47 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $244.28 | 2025 | Omvoh, Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.00 | 2024-2025 | Xifaxan, Trulance, Relistor |
| Gilead Sciences, INC. | $181.73 | 2025 | Livdelzi |
| Regeneron Healthcare Solutions, INC. | $175.27 | 2024-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $138.37 | 2025 | Entyvio |
| Janssen Scientific Affairs, LLC | $114.24 | 2024 | Tremfya |
| Celltrion USA INC. | $73.10 | 2024 | Zymfentra |
| Intercept Pharmaceuticals, INC. | $60.73 | 2024-2025 | |
| Genzyme Corporation | $42.59 | 2024-2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $18.41 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $17.80 | 2024 | Dificid |
| Mauna Kea Technologies, INC. | $17.16 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dakin White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.